Gapping up
In reaction to strong earnings/guidance:
- OLLI +11.4%, PLAB +7.5%, VRA +6.7%, PLAY +1.9%
Other news:
- XERS +11.1% ( reports "positive" topline results from the in-clinic stage of the Phase 2 study of its developmental ready-to-use glucagon in patients at risk of postprandial hypoglycemia following bariatric surgery)
- CHH +9.5% (to join S&P MidCap 400)
- XCUR +8.7% (provides update from Phase 1b/2 trial with AST-008 in patients with solid tumors, says preliminary data show signs of activity in patients with Merkel cell carcinoma)
- WRTC +7.2% (President Tom Smith is scheduled to be interviewed live tomorrow morning at 8:50 a.m. ET in-studio on Morning's With Maria on the Fox Business Network program)
- BCRX +4.9% (submits new drug application to the FDA for approval of oral, once daily berotralstat for the prevention of hereditary angioedema attacks)
- QFIN +4.7% (informed by Hongyi Zhou and certain management that they have reached an agreement with FountainVest Partners to jointly invest up to $60 mln to purchase shares in the next twelve months)
- PCG +2.8% (continued strength)
- LDOS +2.6% (awarded $6.5 bln Defense Information Systems Agency contract)
- PACK +2.2% (prices registered underwritten public offering of 15,384,616 shares of its Class A common stock at a public offering price of $6.50 per share)
- PLT +1.2% (to join S&P SmallCap 600)
Analyst comments:
- FTV +1.6% (upgraded to Overweight at Morgan Stanley)
- REAL +1.4% (initiated with a Buy at DA Davidson)